Skip to main content
Equibles

Sandesh Mahatme

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Sandesh Mahatme

Earlier roles on record: Board Member at Spyre Therapeutics, Inc. (SYRE) until July 8, 2022. Spyre Therapeutics, Inc. reported in an 8-K filed July 7, 2022 that Sandesh Mahatme resigned as Class I director, effective July 8, 2022.

“On July 6, 2022, Sandesh Mahatme advised the Board of Directors (the "Board") of Aeglea BioTherapeutics, Inc. (the "Company") that he would resign as a Class I director of the Board, effective on July 8, 2022.”
Spyre Therapeutics, Inc. Form 8-K, filed July 7, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.